{
    "Clinical Trial ID": "NCT00369655",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment (Ziv-afibercept)",
        "  Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed adenocarcinoma of the breast",
        "  Clinical evidence of metastatic disease",
        "  No more than 2 prior chemotherapy regimens for metastatic disease",
        "  Prior neoadjuvant or adjuvant chemotherapy allowed*",
        "  At least 1 prior regimen (in any setting) must have included a taxane and/or an anthracycline",
        "  Measurable disease, defined as  1 lesion whose longest diameter can be accurately measured per RECIST criteria",
        "  No nonmeasurable disease, defined as all other lesions, including small lesions(longest diameter < 20 mm) and truly nonmeasurable lesions, including the following:",
        "  Bone lesions",
        "  Leptomeningeal disease",
        "  Ascites",
        "  Pleural/pericardial effusion",
        "  Inflammatory breast disease",
        "  Lymphangitis cutis/pulmonis",
        "  Abdominal masses that are not confirmed and followed by imaging techniques",
        "  Cystic lesions",
        "  Patients with HER2-positive tumors (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization [FISH]) must have received  1 prior trastuzumab (Herceptin\u00ae)-containing regimen in either the adjuvant or metastatic setting, unless there was a contraindication",
        "  No known CNS metastases",
        "  No evidence of leptomeningeal involvement",
        "  Hormone receptor status not specified",
        "  Male or female",
        "  Menopausal status not specified",
        "  ECOG performance status 0-1",
        "  Life expectancy > 3 months",
        "  WBC  3,000/mm\u00b3",
        "  Absolute neutrophil count  1,500/mm\u00b3",
        "  Platelet count  75,000/mm\u00b3",
        "  Hemoglobin > 8.0 g/dL",
        "  Bilirubin  1.5 times upper limit of normal (ULN)",
        "  Alkaline phosphatase  3 times ULN",
        "  AST and ALT  2.5 times ULN",
        "  Creatinine  1.5 times ULN",
        "  Urine protein:creatinine ratio < 1 OR urine protein < 500 mg by 24-hour urine collection",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception during and for 6 months after completion of study treatment",
        "  No significant traumatic injury within the past 4 weeks",
        "  No history of allergy or hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, drug product excipients, or agents chemically or biologically similar to VEGF Trap",
        "  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days",
        "  No nonhealing wound, fracture, or ulcer",
        "  No stage III or IV invasive, nonbreast malignancy within the past 5 years",
        "  No history of lung carcinoma of squamous cell type",
        "  No clinically significant cardiovascular disease, including any of the following:",
        "  Cerebrovascular accident or stroke within the past 6 months",
        "  Uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg OR systolic BP > 180 mm Hg if diastolic blood pressure < 90 mm Hg on  2 separate occasions within the past 3 months",
        "  Myocardial infarction, coronary artery bypass graft, or unstable angina within the past 6 months",
        "  New York Heart Association class III or IV cardiovascular disease",
        "  Serious cardiac arrhythmia requiring medication",
        "  Peripheral vascular disease  grade 2 within the past 6 months",
        "  Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months",
        "  No evidence of bleeding diathesis or uncontrolled coagulopathy",
        "  No active, unresolved infection",
        "  No serious concurrent medical condition that would preclude study participation",
        "  No other condition or circumstance that would preclude compliance with study requirements",
        "  See Disease Characteristics",
        "  Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting allowed",
        "  No prior bevacizumab",
        "  More than 4 weeks since prior chemotherapy, endocrine therapy, experimental drug therapy, or immunotherapy and recovered",
        "  More than 4 weeks since prior major surgery or open biopsy",
        "  More than 7 days since prior core biopsy",
        "  More than 2 weeks since prior radiotherapy, except if to a nontarget lesion only",
        "  Prior radiotherapy to a target lesion allowed only if there has been clear progression of the lesion since radiotherapy was completed",
        "  Prior single-dose palliative radiotherapy within the past 2 weeks allowed",
        "  No concurrent major surgery",
        "  No concurrent trastuzumab",
        "  Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed provided the following criteria are met:",
        "  INR in-range (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin",
        "  No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)",
        "  No concurrent combination antiretroviral therapy for HIV-positive patients",
        "  No concurrent participation in another investigational clinical trial",
        "  No other concurrent chemotherapeutic agents, endocrine therapy, biologic agents, radiotherapy, or other nonprotocol antitumor therapy"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Proportion of Patients With Confirmed Tumor Response",
        "  Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart.",
        "  Time frame: Up to 5 years",
        "Results 1: ",
        "  Arm/Group Title: Treatment (Ziv-afibercept)",
        "  Arm/Group Description: Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 21",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  Confirmed tumor partial response: 1",
        "  No Confirmed reponse: 20"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 10/21 (47.62%)",
        "  Left ventricular failure 2/21 (9.52%)",
        "  Sinus tachycardia 1/21 (4.76%)",
        "  Abdominal pain 1/21 (4.76%)",
        "  Disease progression 1/21 (4.76%)",
        "  Platelet count decreased 1/21 (4.76%)",
        "  Anorexia 1/21 (4.76%)",
        "  Headache 2/21 (9.52%)",
        "  Ischemia cerebrovascular 1/21 (4.76%)",
        "  Proteinuria 1/21 (4.76%)",
        "  Dyspnea 2/21 (9.52%)",
        "  Hypertension 2/21 (9.52%)"
    ]
}